Germany · Delayed Price · Currency is EUR Opus Genetics Statistics
Total Valuation
Opus Genetics has a market cap or net worth of EUR 118.65 million. The enterprise value is 93.06 million.
| Market Cap | 118.65M |
| Enterprise Value | 93.06M |
Important Dates
The next estimated earnings date is Monday, March 30, 2026.
| Earnings Date | Mar 30, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 68.96M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +99.64% |
| Shares Change (QoQ) | +11.46% |
| Owned by Insiders (%) | 14.60% |
| Owned by Institutions (%) | 35.12% |
| Float | 37.87M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 9.51 |
| PB Ratio | 23.33 |
| P/TBV Ratio | 23.33 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -1.60 |
| EV / Sales | 7.39 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.23, with a Debt / Equity ratio of 0.18.
| Current Ratio | 1.23 |
| Quick Ratio | 1.21 |
| Debt / Equity | 0.18 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -546.69 |
Financial Efficiency
Return on equity (ROE) is -338.75% and return on invested capital (ROIC) is -112.42%.
| Return on Equity (ROE) | -338.75% |
| Return on Assets (ROA) | -60.73% |
| Return on Invested Capital (ROIC) | -112.42% |
| Return on Capital Employed (ROCE) | -528.43% |
| Revenue Per Employee | 692,873 |
| Profits Per Employee | -3.23M |
| Employee Count | 18 |
| Asset Turnover | 0.38 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +86.67% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +86.67% |
| 50-Day Moving Average | 1.65 |
| 200-Day Moving Average | 1.09 |
| Relative Strength Index (RSI) | 59.72 |
| Average Volume (20 Days) | 434 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.85 |
Income Statement
In the last 12 months, Opus Genetics had revenue of EUR 12.47 million and -58.13 million in losses. Loss per share was -1.17.
| Revenue | 12.47M |
| Gross Profit | -10.90M |
| Operating Income | -31.68M |
| Pretax Income | -58.13M |
| Net Income | -58.13M |
| EBITDA | -31.65M |
| EBIT | -31.68M |
| Loss Per Share | -1.17 |
Balance Sheet
The company has 26.26 million in cash and 910,256 in debt, giving a net cash position of 25.35 million.
| Cash & Cash Equivalents | 26.26M |
| Total Debt | 910,256 |
| Net Cash | 25.35M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 5.09M |
| Book Value Per Share | 0.08 |
| Working Capital | 5.82M |
Cash Flow
| Operating Cash Flow | -28.00M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | -87.37% |
| Operating Margin | -254.05% |
| Pretax Margin | -466.09% |
| Profit Margin | n/a |
| EBITDA Margin | -253.74% |
| EBIT Margin | -254.05% |
| FCF Margin | n/a |
Dividends & Yields
Opus Genetics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -99.64% |
| Shareholder Yield | -99.64% |
| Earnings Yield | -48.99% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Opus Genetics has an Altman Z-Score of -8.45 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -8.45 |
| Piotroski F-Score | 3 |